Agtc

AGTC, a biotechnology company, focuses on developing AAV-based gene therapies to treat rare diseases. Founded with the mission to transform lives through pioneering ocular gene therapy, AGTC is dedicated to saving and restoring vision for patients suffering from various prevalent and rare ophthalmic conditions. The company is currently conducting human clinical trials, including the VISTA trial for X-Linked Retinitis Pigmentosa, and offers no-cost genetic testing and prescreening for eligible participants.

Notable figures affiliated with AGTC include experienced scientists and researchers in the field of gene therapy. The company has garnered significant investment from leading biotech venture capital firms. Key achievements include advancing multiple gene therapy candidates into clinical trials and making substantial progress in the treatment of rare ocular diseases. AGTC's innovative approach has had a profound impact on the biotechnology landscape, offering hope to patients with previously untreatable conditions.